Search CTL/CD8+ T-Cell Epitope Database

Found 9 matching records:

Displaying record number 58394

HXB2 Location	Gag(325-333) p24(193-201) DNA(1762..1788)	Gag Epitope Map
Author Location	Gag(327-335 IIIB, MN)
Epitope	NANPDCKTI	Epitope Alignment
		Show epitope variants
Epitope Name	NI9
Subtype	B
Species (MHC/HLA)	human(B*51)
Immunogen	HIV-1 infection
Country	China
Experimental methods	CD8 T-cell Elispot - IFNγ, CTL suppression of replication
Keywords	rate of progression, immunodominance, escape, HLA associated polymorphism, elite controllers

Notes

• To study the beneficial effects of HLA-B*51 without confounding founder effects, 22 HLA-B*51+ subjects selected from a Chinese cohort of plasma-route HIV-infected individuals, without ART for 10 years, were studied. Progression to AIDS was associated with sequential mutation selection and subsequent CTL response within 3 immunodominant epitopes, in order - Pol LPPVVAKEI (LI9), followed by Gag NANPDCKTI (NI9) and then Pol TAFTIPSI (TI8). Thus a multi-layered response is suggested to be beneficial for control in B*51-carrying controllers.
• The order of mutations in HIV-1 appears to be the L743I mutation at position 1 of the LI9 epitope followed by the V289L mutation at position 8 of TV8 epitope and then the A328S mutation in position 2 of the NI9 epitope.
• Epitope NANPDCKTI, NI9, was the second-most immunodominant in HLA-B51+ subjects, with 64% frequency of recognition with a mean magnitude of >1000 SFU/million PBMC when CTL response is measured by ex vivo EliSpot. 8/22 B-51+ and 97/126 B-51- subjects carried this wild type sequence. Mutations in NI9 are associated with low CD4+ counts in HLA-B51+ subjects.

References

Zhang2011 YongHong Zhang, YanChun Peng, HuiPing Yan, Keyi Xu, Masumichi Saito, Hao Wu, XinYue Chen, Srinika Ranasinghe, Nozomi Kuse, Tim Powell, Yan Zhao, WeiHua Li, Xin Zhang, Xia Feng, Ning Li, Aleksandra Leligdowicz, XiaoNing Xu, Mina John, Masafumi Takiguchi, Andrew McMichael, Sarah Rowland-Jones, and Tao Dong. Multilayered Defense in HLA-B51-Associated HIV Viral Control. J. Immunol., 187(2):684-691, 15 Jul 2011. PubMed ID: 21670313. Show all entries for this paper.

---

Displaying record number 58395

HXB2 Location	Pol(283-290) RT(128-135) DNA(2931..2954)	Pol Epitope Map
Author Location	Pol(283-289 IIIB, MN)
Epitope	TAFTIPSV	Epitope Alignment
		Show epitope variants
Epitope Name	TV8
Subtype	B
Species (MHC/HLA)	human(B*51)
Immunogen	HIV-1 infection
Country	China
Experimental methods	CD8 T-cell Elispot - IFNγ, CTL suppression of replication
Keywords	rate of progression, HLA associated polymorphism, elite controllers

Notes

• To study the beneficial effects of HLA-B*51 without confounding founder effects, 22 HLA-B*51+ subjects selected from a Chinese cohort of plasma-route HIV-infected individuals, without ART for 10 years, were studied. Progression to AIDS was associated with sequential mutation selection and subsequent CTL response within 3 immunodominant epitopes, in order - Pol LPPVVAKEI (LI9), followed by Gag NANPDCKTI (NI9) and then Pol TAFTIPSI (TI8). Thus a multi-layered response is suggested to be beneficial for control in B*51-carrying controllers.
• The order of mutations in HIV-1 appears to be the L743I mutation at position 1 of the LI9 epitope followed by the V289L mutation at position 8 of TV8 epitope and then the A328S mutation in position 2 of the NI9 epitope.
• Epitope TAFTIPSV, TV8, was the third-most immunodominant in HLA-B51+ subjects, with 42% frequency of recognition and a mean magnitude of ˜500 SFU/million PBMC when CTL response is measured by ex vivo EliSpot. 15/22 B-51+ and 123/126 B-51- subjects carried this wild type sequence. Since a significantly higher viral load is seen when TV8 is mutated, it is suggested that mutations in TV8 are associated with loss of viral control in HLA-B51+ subjects.

References

Zhang2011 YongHong Zhang, YanChun Peng, HuiPing Yan, Keyi Xu, Masumichi Saito, Hao Wu, XinYue Chen, Srinika Ranasinghe, Nozomi Kuse, Tim Powell, Yan Zhao, WeiHua Li, Xin Zhang, Xia Feng, Ning Li, Aleksandra Leligdowicz, XiaoNing Xu, Mina John, Masafumi Takiguchi, Andrew McMichael, Sarah Rowland-Jones, and Tao Dong. Multilayered Defense in HLA-B51-Associated HIV Viral Control. J. Immunol., 187(2):684-691, 15 Jul 2011. PubMed ID: 21670313. Show all entries for this paper.

---

Displaying record number 58381

HXB2 Location	Pol(743-751) Integrase(28-36) DNA(4311..4337)	Pol Epitope Map
Author Location	Pol(743-750 IIIB, MN)
Epitope	LPPVVAKEI	Epitope Alignment
		Show epitope variants
Epitope Name	LI9
Subtype	B
Species (MHC/HLA)	human(B*51)
Immunogen	HIV-1 infection
Country	China
Experimental methods	CD8 T-cell Elispot - IFNγ, CTL suppression of replication
Keywords	rate of progression, HLA associated polymorphism, elite controllers

Notes

• To study the beneficial effects of HLA-B*51 without confounding founder effects, 22 HLA-B*51+ subjects selected from a Chinese cohort of plasma-route HIV-infected individuals, without ART for 10 years, were studied. Progression to AIDS was associated with sequential mutation selection and subsequent CTL response within 3 immunodominant epitopes, in order - Pol LPPVVAKEI (LI9), followed by Gag NANPDCKTI (NI9) and then Pol TAFTIPSI (TI8). Thus a multi-layered response is suggested to be beneficial for control in B*51-carrying controllers.
• The order of mutations in HIV-1 appears to be the L743I mutation at position 1 of the LI9 epitope followed by the V289L mutation at position 8 of TV8 epitope and then the A328S mutation in position 2 of the NI9 epitope.
• Epitope LPPVVAKEI, LI9, was the most immunodominant in HLA-B51+ subjects, with 72% frequency of recognition and a mean magnitude of >500 SFU/million PBMC when CTL response is measured by ex vivo EliSpot. 5/22 B-51+ and 114/126 B-51- subjects carried this wild type sequence. Since a significantly higher viral load is seen when LI9 is mutated, it is suggested that mutations in LI9 are associated with loss of viral control in HLA-B51+ subjects.

References

Zhang2011 YongHong Zhang, YanChun Peng, HuiPing Yan, Keyi Xu, Masumichi Saito, Hao Wu, XinYue Chen, Srinika Ranasinghe, Nozomi Kuse, Tim Powell, Yan Zhao, WeiHua Li, Xin Zhang, Xia Feng, Ning Li, Aleksandra Leligdowicz, XiaoNing Xu, Mina John, Masafumi Takiguchi, Andrew McMichael, Sarah Rowland-Jones, and Tao Dong. Multilayered Defense in HLA-B51-Associated HIV Viral Control. J. Immunol., 187(2):684-691, 15 Jul 2011. PubMed ID: 21670313. Show all entries for this paper.

---

Displaying record number 58399

HXB2 Location	Vif(57-66) DNA(5209..5238)	Vif Epitope Map
Author Location	( IIIB, MN)
Epitope	IPLGDAKLII	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B*51)
Immunogen	HIV-1 infection
Country	China
Experimental methods	CD8 T-cell Elispot - IFNγ, CTL suppression of replication
Keywords	rate of progression, HLA associated polymorphism, elite controllers

Notes

• To study the beneficial effects of HLA-B*51 without confounding founder effects, 22 HLA-B*51+ subjects selected from a Chinese cohort of plasma-route HIV-infected individuals, without ART for 10 years, were studied. Progression to AIDS was associated with sequential mutation selection and subsequent CTL response within 3 immunodominant epitopes, in order - Pol LPPVVAKEI (LI9), followed by Gag NANPDCKTI (NI9) and then Pol TAFTIPSI (TI8). Thus a multi-layered response is suggested to be beneficial for control in B*51-carrying controllers.
• The order of mutations in HIV-1 appears to be the L743I mutation at position 1 of the LI9 epitope followed by the V289L mutation at position 8 of TV8 epitope and then the A328S mutation in position 2 of the NI9 epitope.
• Epitope IPLGDAKLII had a <20% frequency of recognition and a mean magnitude of >300 SFU/million PBMC when CTL response is measured by ex vivo EliSpot in HLA-B51+ subjects.

References

Zhang2011 YongHong Zhang, YanChun Peng, HuiPing Yan, Keyi Xu, Masumichi Saito, Hao Wu, XinYue Chen, Srinika Ranasinghe, Nozomi Kuse, Tim Powell, Yan Zhao, WeiHua Li, Xin Zhang, Xia Feng, Ning Li, Aleksandra Leligdowicz, XiaoNing Xu, Mina John, Masafumi Takiguchi, Andrew McMichael, Sarah Rowland-Jones, and Tao Dong. Multilayered Defense in HLA-B51-Associated HIV Viral Control. J. Immunol., 187(2):684-691, 15 Jul 2011. PubMed ID: 21670313. Show all entries for this paper.

---

Displaying record number 58400

HXB2 Location	Vpr(29-37) DNA(5643..5669)	Vpr Epitope Map
Author Location	( IIIB, MN)
Epitope	EAVRHFPRI	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B*51)
Immunogen	HIV-1 infection
Country	China
Experimental methods	CD8 T-cell Elispot - IFNγ, CTL suppression of replication
Keywords	rate of progression, HLA associated polymorphism, elite controllers

Notes

• To study the beneficial effects of HLA-B*51 without confounding founder effects, 22 HLA-B*51+ subjects selected from a Chinese cohort of plasma-route HIV-infected individuals, without ART for 10 years, were studied. Progression to AIDS was associated with sequential mutation selection and subsequent CTL response within 3 immunodominant epitopes, in order - Pol LPPVVAKEI (LI9), followed by Gag NANPDCKTI (NI9) and then Pol TAFTIPSI (TI8). Thus a multi-layered response is suggested to be beneficial for control in B*51-carrying controllers.
• The order of mutations in HIV-1 appears to be the L743I mutation at position 1 of the LI9 epitope followed by the V289L mutation at position 8 of TV8 epitope and then the A328S mutation in position 2 of the NI9 epitope.
• Epitope EAVRHFPRI had a <20% frequency of recognition and a mean magnitude of >300 SFU/million PBMC when CTL response is measured by ex vivo EliSpot in HLA-B51+ subjects.

References

Zhang2011 YongHong Zhang, YanChun Peng, HuiPing Yan, Keyi Xu, Masumichi Saito, Hao Wu, XinYue Chen, Srinika Ranasinghe, Nozomi Kuse, Tim Powell, Yan Zhao, WeiHua Li, Xin Zhang, Xia Feng, Ning Li, Aleksandra Leligdowicz, XiaoNing Xu, Mina John, Masafumi Takiguchi, Andrew McMichael, Sarah Rowland-Jones, and Tao Dong. Multilayered Defense in HLA-B51-Associated HIV Viral Control. J. Immunol., 187(2):684-691, 15 Jul 2011. PubMed ID: 21670313. Show all entries for this paper.

---

Displaying record number 58401

HXB2 Location	gp160(557-565) gp41(46-54) DNA(7893..7919)	gp160 Epitope Map
Author Location	( IIIB, MN)
Epitope	RAIEAQQHL	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B*51)
Immunogen	HIV-1 infection
Country	China
Experimental methods	CD8 T-cell Elispot - IFNγ, CTL suppression of replication
Keywords	rate of progression, HLA associated polymorphism, elite controllers

Notes

• To study the beneficial effects of HLA-B*51 without confounding founder effects, 22 HLA-B*51+ subjects selected from a Chinese cohort of plasma-route HIV-infected individuals, without ART for 10 years, were studied. Progression to AIDS was associated with sequential mutation selection and subsequent CTL response within 3 immunodominant epitopes, in order - Pol LPPVVAKEI (LI9), followed by Gag NANPDCKTI (NI9) and then Pol TAFTIPSI (TI8). Thus a multi-layered response is suggested to be beneficial for control in B*51-carrying controllers.
• The order of mutations in HIV-1 appears to be the L743I mutation at position 1 of the LI9 epitope followed by the V289L mutation at position 8 of TV8 epitope and then the A328S mutation in position 2 of the NI9 epitope.
• Epitope RAIEAQQHL had a <20% frequency of recognition and a mean magnitude of >100 SFU/million PBMC when CTL response is measured by ex vivo EliSpot in HLA-B51+ subjects.

References

Zhang2011 YongHong Zhang, YanChun Peng, HuiPing Yan, Keyi Xu, Masumichi Saito, Hao Wu, XinYue Chen, Srinika Ranasinghe, Nozomi Kuse, Tim Powell, Yan Zhao, WeiHua Li, Xin Zhang, Xia Feng, Ning Li, Aleksandra Leligdowicz, XiaoNing Xu, Mina John, Masafumi Takiguchi, Andrew McMichael, Sarah Rowland-Jones, and Tao Dong. Multilayered Defense in HLA-B51-Associated HIV Viral Control. J. Immunol., 187(2):684-691, 15 Jul 2011. PubMed ID: 21670313. Show all entries for this paper.

---

Displaying record number 58402

HXB2 Location	Nef(72-81) DNA(9010..9039)	Nef Epitope Map
Author Location	( IIIB, MN)
Epitope	PQVPLRPMTY	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B*51)
Immunogen	HIV-1 infection
Country	China
Experimental methods	CD8 T-cell Elispot - IFNγ, CTL suppression of replication
Keywords	rate of progression, HLA associated polymorphism, elite controllers

Notes

• To study the beneficial effects of HLA-B*51 without confounding founder effects, 22 HLA-B*51+ subjects selected from a Chinese cohort of plasma-route HIV-infected individuals, without ART for 10 years, were studied. Progression to AIDS was associated with sequential mutation selection and subsequent CTL response within 3 immunodominant epitopes, in order - Pol LPPVVAKEI (LI9), followed by Gag NANPDCKTI (NI9) and then Pol TAFTIPSI (TI8). Thus a multi-layered response is suggested to be beneficial for control in B*51-carrying controllers.
• The order of mutations in HIV-1 appears to be the L743I mutation at position 1 of the LI9 epitope followed by the V289L mutation at position 8 of TV8 epitope and then the A328S mutation in position 2 of the NI9 epitope.
• Epitope PQVPLRPMTY had a <20% frequency of recognition and a mean magnitude of ∼100 SFU/million PBMC when CTL response is measured by ex vivo EliSpot in HLA-B51+ subjects.

References

Zhang2011 YongHong Zhang, YanChun Peng, HuiPing Yan, Keyi Xu, Masumichi Saito, Hao Wu, XinYue Chen, Srinika Ranasinghe, Nozomi Kuse, Tim Powell, Yan Zhao, WeiHua Li, Xin Zhang, Xia Feng, Ning Li, Aleksandra Leligdowicz, XiaoNing Xu, Mina John, Masafumi Takiguchi, Andrew McMichael, Sarah Rowland-Jones, and Tao Dong. Multilayered Defense in HLA-B51-Associated HIV Viral Control. J. Immunol., 187(2):684-691, 15 Jul 2011. PubMed ID: 21670313. Show all entries for this paper.

---

Displaying record number 58398

HXB2 Location	Nef(120-128) DNA(9154..9180)	Nef Epitope Map
Author Location	( IIIB, MN)
Epitope	YFPDWQNYT	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B*51)
Immunogen	HIV-1 infection
Country	China
Experimental methods	CD8 T-cell Elispot - IFNγ, CTL suppression of replication
Keywords	rate of progression, HLA associated polymorphism, elite controllers

Notes

• To study the beneficial effects of HLA-B*51 without confounding founder effects, 22 HLA-B*51+ subjects selected from a Chinese cohort of plasma-route HIV-infected individuals, without ART for 10 years, were studied. Progression to AIDS was associated with sequential mutation selection and subsequent CTL response within 3 immunodominant epitopes, in order - Pol LPPVVAKEI (LI9), followed by Gag NANPDCKTI (NI9) and then Pol TAFTIPSI (TI8). Thus a multi-layered response is suggested to be beneficial for control in B*51-carrying controllers.
• The order of mutations in HIV-1 appears to be the L743I mutation at position 1 of the LI9 epitope followed by the V289L mutation at position 8 of TV8 epitope and then the A328S mutation in position 2 of the NI9 epitope.
• Epitope YFPDWQNYT had a >20% frequency of recognition and a mean magnitude of >500 SFU/million PBMC when CTL response is measured by ex vivo EliSpot in HLA-B51+ subjects.

References

Zhang2011 YongHong Zhang, YanChun Peng, HuiPing Yan, Keyi Xu, Masumichi Saito, Hao Wu, XinYue Chen, Srinika Ranasinghe, Nozomi Kuse, Tim Powell, Yan Zhao, WeiHua Li, Xin Zhang, Xia Feng, Ning Li, Aleksandra Leligdowicz, XiaoNing Xu, Mina John, Masafumi Takiguchi, Andrew McMichael, Sarah Rowland-Jones, and Tao Dong. Multilayered Defense in HLA-B51-Associated HIV Viral Control. J. Immunol., 187(2):684-691, 15 Jul 2011. PubMed ID: 21670313. Show all entries for this paper.

---

Displaying record number 58403

HXB2 Location	Nef(186-194) DNA(9352..9378)	Nef Epitope Map
Author Location	( IIIB, MN)
Epitope	DSRLAFHHV	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B*51)
Immunogen	HIV-1 infection
Country	China
Experimental methods	CD8 T-cell Elispot - IFNγ, CTL suppression of replication
Keywords	rate of progression, HLA associated polymorphism, elite controllers

Notes

• To study the beneficial effects of HLA-B*51 without confounding founder effects, 22 HLA-B*51+ subjects selected from a Chinese cohort of plasma-route HIV-infected individuals, without ART for 10 years, were studied. Progression to AIDS was associated with sequential mutation selection and subsequent CTL response within 3 immunodominant epitopes, in order - Pol LPPVVAKEI (LI9), followed by Gag NANPDCKTI (NI9) and then Pol TAFTIPSI (TI8). Thus a multi-layered response is suggested to be beneficial for control in B*51-carrying controllers.
• The order of mutations in HIV-1 appears to be the L743I mutation at position 1 of the LI9 epitope followed by the V289L mutation at position 8 of TV8 epitope and then the A328S mutation in position 2 of the NI9 epitope.
• Epitope DSRLAFHHV had a <20% frequency of recognition and a mean magnitude of ∼100 SFU/million PBMC when CTL response is measured by ex vivo EliSpot in HLA-B51+ subjects.

References

Zhang2011 YongHong Zhang, YanChun Peng, HuiPing Yan, Keyi Xu, Masumichi Saito, Hao Wu, XinYue Chen, Srinika Ranasinghe, Nozomi Kuse, Tim Powell, Yan Zhao, WeiHua Li, Xin Zhang, Xia Feng, Ning Li, Aleksandra Leligdowicz, XiaoNing Xu, Mina John, Masafumi Takiguchi, Andrew McMichael, Sarah Rowland-Jones, and Tao Dong. Multilayered Defense in HLA-B51-Associated HIV Viral Control. J. Immunol., 187(2):684-691, 15 Jul 2011. PubMed ID: 21670313. Show all entries for this paper.

---